TITLE

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

AUTHOR(S)
Zhang, Sensen; Xu, Jiaren; Wu, Shuang; Wang, Rong; Qu, Xiaoyan; Yu, Wenjun; Li, Jiangyong; Chen, Lijuan
PUB. DATE
June 2013
SOURCE
Medical Oncology;Jun2013, Vol. 30 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
87820232

 

Related Articles

  • Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Barbarulo, A; Iansante, V; Chaidos, A; Naresh, K; Rahemtulla, A; Franzoso, G; Karadimitris, A; Haskard, D O; Papa, S; Bubici, C // Oncogene;9/5/2013, Vol. 32 Issue 36, p4231 

    Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM). Jun N-terminal kinase (JNK) signaling has been implicated in MM pathogenesis, but its function is unclear. To elucidate the role of JNK in MM, we evaluated the specific functions of the two major JNK...

  • IRF4 addiction in multiple myeloma. Shaffer, Arthur L.; Emre, N. C. Tolga; Lamy, Laurence; Ngo, Vu N.; Wright, George; Wenming Xiao; Powell, John; Dave, Sandeep; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Epstein, Joshua; Staudt, Louis M. // Nature;7/10/2008, Vol. 454 Issue 7201, p226 

    The transcription factor IRF4 (interferon regulatory factor 4) is required during an immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells. Multiple myeloma, a malignancy of plasma cells, has a complex molecular aetiology with several subgroups...

  • c-Jun N-terminal kinase (JNK1) upregulates XIAP-associated factor 1 (XAF1) through interferon regulatory factor 1 (IRF-1) in gastrointestinal cancer. Jide Wang; Wenjing Zhang; Yusheng Zhang; Ye Chen; Bing Zou; Bo Jiang; Pang, Roberta; Qing Gu; Liang Qiao; Huiyao Lan; Hsiang-Fu Kung; Wong, Benjamin C. Y. // Carcinogenesis;Feb2009, Vol. 30 Issue 2, p222 

    Background and Aims: X-linked inhibitor of apoptosis protein-associated factor 1 (XAF1) is a tumor suppressor that can sensitize cancer cell to apoptosis. Intrinsic expression of XAF1 in cancer cell is low. Our purpose is to determine the effect of c-Jun N-terminal kinase 1 (JNK1) on XAF1...

  • Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Chim, C.S.; Fung, T.K.; Liang, R. // Leukemia (08876924);Dec2003, Vol. 17 Issue 12, p2533 

    Presents a letter to the editor of "Leukemia" journal concerning aberrant gene promoter methylation in patients with multiple myeloma. Cancer cell proliferation; Monoclonal gammopathy of undetermined significance; Cell cycle checkpoints.

  • In Brief.  // Nature Reviews Immunology;Aug2008, Vol. 8 Issue 8, p573 

    The article offers news briefs related to immunology researches. The RNA-interference-based screening method identifies the interferon-regulatory factor 4 (IRF4) as regulator of aberrant gene expression in multiple myeloma. A research shows that a proliferating ligand (APRIL) is concentrated in...

  • Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. Saha, Manujendra N.; Jiang, Hua; Yang, Yijun; Zhu, Xiaoyun; Wang, Xiaoming; Schimmer, Aaron D.; Qiu, Lugui; Chang, Hong // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The low frequency of p53 alterations e.g., mutations/deletions (~10%) in multiple myeloma (MM) makes this tumor type an ideal candidate for p53-targeted therapies. RITA is a small molecule which can induce apoptosis in tumor cells by activating the p53 pathway. We previously showed that RITA...

  • Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. Saha, Manujendra N.; Jiang, Hua; Yang, Yijun; Zhu, Xiaoyun; Wang, Xiaoming; Schimmer, Aaron D.; Qiu, Lugui; Chang, Hong // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes this tumor type an ideal candidate for p53-targeted therapies. RITA is a small molecule which can induce apoptosis in tumor cells by activating the p53 pathway. We previously showed that...

  • Cancer: An unexpected addiction. Shaughnessy, John D. // Nature;7/10/2008, Vol. 454 Issue 7201, p172 

    The article focuses on a study regarding cancer multiple myeloma, a cancer of antibody-secreting plasma cells in bone marrow where researchers found that the cancer is similarly addicted to non-oncogene. They screened 10% percent of known cells, using the technique of RNA interference (RNAi)...

  • Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Kobayashi, T.; Kuroda, J.; Ashihara, E.; Oomizu, S.; Terui, Y.; Taniyama, A.; Adachi, S.; Takagi, T.; Yamamoto, M.; Sasaki, N.; Horiike, S.; Hatake, K.; Yamauchi, A.; Hirashima, M.; Taniwaki, M. // Leukemia (08876924);Apr2010, Vol. 24 Issue 4, p843 

    Galectins constitute a family of lectins that specifically exhibit the affinity for β-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate recognition domains and has recently been shown to have an anti-proliferative effect on...

  • Elevated JNK activation contributes to the pathogenesis of human brain tumors. Antonyak, Marc A.; Kenyon, Lawrence C.; Godwin, Andrew K.; James, David C.; Emlet, David R.; Okamoto, Isamu; Tnani, Mehdi; Holgado-Madruga, Marina; Moscatello, David K.; Wong, Albert J. // Oncogene;8/1/2002, Vol. 21 Issue 33, p5038 

    Presents a study that analyzed the role of the JNK pathway in the promotion of tumorigenesis. Discussion on tumors and cell lines; Details on the application of Western blot analysis in the study; Analysis of the significance of JNK in the promotion of cell growth.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics